The role of von Willebrand factor in thrombotic microangiopathy (original) (raw)
Thrombotic Microangiopathies and the Linkage between von Willebrand Factor and the Alternative Complement Pathway
Jennifer Nolasco
Thrombotic Microangiopathies and the Linkage between von Willebrand Factor and the Alternative Complement Pathway
View PDFchevron_right
Spectrum of Complement-Mediated Thrombotic Microangiopathies: Pathogenetic Insights Identifying Novel Treatment Approaches
Magdalena Riedl, Damien Noone
Seminars in Thrombosis and Hemostasis, 2014
View PDFchevron_right
An update on the thrombotic microangiopathies hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP)
Magdalena Riedl
Seminars in thrombosis and hemostasis, 2014
View PDFchevron_right
The molecular biology of thrombotic microangiopathy
HAN-MOU TSAI
Kidney International, 2006
View PDFchevron_right
TTP-like syndrome: novel concept and molecular pathogenesis of endotheliopathy-associated vascular microthrombotic disease
Jae Chang
Thrombosis Journal, 2018
View PDFchevron_right
Pathogenesis of Atypical Hemolytic Uremic Syndrome
Yoichiro Ikeda
Journal of Atherosclerosis and Thrombosis, 2018
View PDFchevron_right
aHUS caused by complement dysregulation: new therapies on the horizon
Christoph Licht
Pediatric Nephrology, 2010
View PDFchevron_right
Pathogenesis of thrombotic microangiopathies
Long Zheng
2008
View PDFchevron_right
Advances in understanding of pathogenesis of aHUS and HELLP
David Kavanagh
British Journal of Haematology, 2008
View PDFchevron_right
Relative Role of Genetic Complement Abnormalities in Sporadic and Familial aHUS and Their Impact on Clinical Phenotype
Marina Noris
Clinical Journal of the American Society of Nephrology, 2010
View PDFchevron_right
Not known from ADAM(TS-13)--novel insights into the pathophysiology of thrombotic microangiopathies
Gunter Wolf
Nephrology Dialysis Transplantation, 2004
View PDFchevron_right
Complement in Secondary Thrombotic Microangiopathy
Sanjeev Sethi
Kidney International Reports
View PDFchevron_right
The combined roles of ADAMTS13 and VWF in murine models of TTP, endotoxemia, and thrombosis
Anil Chauhan
Blood, 2008
View PDFchevron_right
Thrombotic Microangiopathies, Thrombotic Thrombocytopenic Purpura, and ADAMTS-13
Gianna Mastroianni Kirsztajn
Seminars in Thrombosis and Hemostasis, 2012
View PDFchevron_right
The combined roles ofADAMTS13 and VWF in murine models of TTP, endotoxemia, and thrombosis. Commentary
Anil Chauhan
Blood, 2008
View PDFchevron_right
Alternative complement pathway assessment in patients with atypical HUS
Marie-Agnès Dragon-Durey
Journal of Immunological Methods, 2011
View PDFchevron_right
Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS
R. Cofiell
Blood, 2015
View PDFchevron_right
The Alternative Pathway of Complement and the Evolving Clinical-Pathophysiological Spectrum of Atypical Hemolytic Uremic Syndrome
Bruce Berger
The American journal of the medical sciences, 2016
View PDFchevron_right
Complement activation in thrombotic thrombocytopenic purpura
K. Rázsó, M. Réti
Journal of Thrombosis and Haemostasis, 2012
View PDFchevron_right
Severe deficiency of VWF-cleaving protease (ADAMTS13) activity defines a distinct population of thrombotic microangiopathy patients
T. Raife
Transfusion, 2004
View PDFchevron_right
Atypical Hemolytic Uremic Syndrome: Differential Diagnosis from TTP/HUS and Management
Mustafa Yenerel
Turkish Journal of Hematology, 2014
View PDFchevron_right
Factor I Autoantibodies in Patients with Atypical Hemolytic Uremic Syndrome: Disease-Associated or an Epiphenomenon?
David Kavanagh
Clinical Journal of the American Society of Nephrology, 2012
View PDFchevron_right
Two novel ADAMTS13 gene mutations in thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome (TTP/HUS)
Thorsten Simon
Kidney International, 2004
View PDFchevron_right
Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies
Johanna Kremer
Journal of Thrombosis and Haemostasis, 2011
View PDFchevron_right
Molecular Pathogenesis of Endotheliopathy and Endotheliopathic Syndromes, Leading to Inflammation and Microthrombosis, and Various Hemostatic Clinical Phenotypes Based on “Two-Activation Theory of the Endothelium” and “Two-Path Unifying Theory” of Hemostasis
Jae Chang
Medicina
View PDFchevron_right
Autoantibodies to CD59, CD55, CD46 or CD35 are not associated with atypical haemolytic uraemic syndrome (aHUS)
David Kavanagh
Molecular Immunology, 2015
View PDFchevron_right
von Willebrand factor and thrombotic thrombocytopenic purpura
T. Raife
Current Opinion in Hematology, 2000
View PDFchevron_right
Autoimmunity: Homeostasis of Innate Immunity Gone Awry
Patty Atkinson
Journal of Clinical Immunology, 2012
View PDFchevron_right
Evaluation of complement regulatory components in patients with atypical hemolytic uremic syndrome
Akbar Dorgalaleh
Central European Journal of Immunology, 2014
View PDFchevron_right
Does complement factor B have a role in the pathogenesis of atypical HUS?
David Kavanagh
Molecular Immunology, 2006
View PDFchevron_right
An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document
MANUEL ARIAS
Nefrología : publicación oficial de la Sociedad Española Nefrologia, 2013
View PDFchevron_right
Atypical hemolytic uremic syndrome: a syndrome in need of clarity
Bruce Berger
Clinical Kidney Journal, 2018
View PDFchevron_right
Comprehensive analysis of glomerular mRNA expression of pro- and antithrombotic genes in atypical haemolytic-uremic syndrome (aHUS)
Thurid Ahlenstiel
Virchows Archiv, 2013
View PDFchevron_right
Advances in the pathogenesis, diagnosis and treatment of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome
Dino Veneri
Thrombosis Research, 2006
View PDFchevron_right
Thrombotic thrombocytopenic purpura and other thrombotic microangiopathic hemolytic anemias: Diagnosis and classification
Yulia Einav
2014
View PDFchevron_right